The entries of “Technologies made in Vienna” are displayed in the project language.
Technologies from Vienna
ORIGIMM Biotechnology GmbH
Vaccines targeting dermatological conditions and implant associated infectionsOrigimm specializes in discovery of antigens and functional drug targets for the prevention and treatment of infectious diseases and microbe-associated dermatological conditions. The company uses its proprietary ProVaDis technology to identify highly protective antigens by reverse functional screening.
Origimm’s lead programs are a therapeutic vaccine against Propionibacterium acnes to treat acne vulgaris and a prophylactic vaccine to prevent implant associated P. acnes infections.
Origimm strives to establish itself as a leader in non-conventional research that delivers superior preventive and therapeutic solutions. By focusing on the pathologic conditions caused by the skin-colonizing microbes, Origimm operates primarily in the biotech branch of human vaccines targeting
dermatological conditions and implant associated infections.
Prevention of implant-associated infections caused by the bacterium S. epidermidisMillions of different medical implants are used in the hospitals every year to substitute missing structure or function in the human body. Despite the improved bio-compatibility and functionality, implants carry a significant risk of infection. Implant-associated infections are the most feared and difficult to treat complications, with considerable mortality and consuming substantial health care cost. These infections are difficult to treat because bacteria create biofilms on the implant surface and so resist antibiotics.
Staphylococcus epidermidis is the most commonly cultured microorganism in implant associated infections, occurring in 30% to 50% of cases, followed by S. aureus and P. acnes.
As a skin commensal bacterium, S.epidermidis can easily gain access to surgical sites during implant insertion surgery. There is currently no satisfactory preventive or therapeutic treatment against implant-associated infections. Origimm will address this large medical need by developing a vaccine against S. epidermidis infections.
Kontakt Wirtschaftsagentur Wien
Information and networking are co-funded by the European Fund for regional development as part of the „IC3 Innovation by Co-Operation, Co-Creation and Community Building“ project. Additional information on the IWB/EFRE funding programme